<DOC>
	<DOCNO>NCT01374568</DOCNO>
	<brief_summary>The purpose study determine use sitagliptin increase bone formation reduces bone turnover postmenopausal woman type 2 diabetes .</brief_summary>
	<brief_title>Changes Bone Turnover With Increased Incretin Hormone Exposure</brief_title>
	<detailed_description>Patients Type 2 Diabetes Mellitus ( T2DM ) increase risk fracture , despite bone mineral density ( BMD ) similar age sex match cohort . Recent study indicate change incretin ( INtestinal seCRETion INsulin ) hormones set T2DM may play role bone metabolism . Two incretin hormone , gastric inhibitory polypeptide ( GIP ) glucagon-like peptide-1 ( GLP-1 ) , show involved bone turnover regulation , addition effect increase insulin secretion decrease glucagon secretion glucose-dependent manner . In addition , rise glucagon-like peptide-2 ( GLP-2 ) postprandial state find direct effect reduce bone resorption non-fasting state treatment GLP-2 improve BMD postmenopausal woman . Due glucose lower effect , incretins therapeutic target treatment T2DM GLP-1 receptor analog inhibition incretin metabolism via dipeptidyl peptidase 4 ( DPP-4 ) inhibitor ( i.e . sitagliptin ) . Inhibition DPP-4 lead approximate double GLP-1 GIP level also lead reduced breakdown GLP-2 . Less known effect incretin-directed therapy , specifically sitagliptin , bone metabolism . To knowledge , two study look direct effect currently available incretin-directed therapy bone metabolism . Exenatide ( GLP-1 analog ) treatment insulin resistant type 2 diabetic rat result osteogenic effect increase osteocalcin level follow treatment . In study female non-diabetic Sprague-Dawley rat treat pioglitazone , rosiglitazone , sitagliptin , vs. placebo , significant change bone mineral density see sitagliptin placebo treat rat ( compare significant loss bone mineral density TZD group ) . Even few publish study available evaluate change bone metabolism use incretin hormone human . The majority human study complete GLP-2 . These study show dose-dependent effect GLP-2 bone resorption , preliminarily , show improve bone mineral density postmenopausal woman treat GLP-2 . However , change incretin activity vary person glucose intolerance T2DM . Therefore , important understand potential effect medication bone metabolism person prescribe medication treatment T2DM .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Postmenopausal woman ( defined age &gt; 55 year old amenorrhea &gt; 1years ) Type 2 DM currently diabetesspecific medication ( ) treat monotherapy metformin sulfonylurea . Patients treat insulin monotherapy also eligible total daily dose insulin &lt; 10units . Hemoglobin A1c ( HbA1c ) 6.59.0 % Use incretin mimetic ( i.e . exenatide ) , DPP4 inhibitor ( i.e . sitagliptin , saxagliptin ) , thiazolidinedione , oral glucocorticoid 6 month prior study eligible Known osteoporosis patient treat osteoporosisspecific medication ( bisphosphonate , teriparatide ) estrogen ( include Selective Estrogen Receptor Modulators ( SERMs ) ) anticipate imminent treatment one medication exclude study Chronic kidney disease ( calculate GFR &lt; 30 ml/min ) disease know affect bone turnover ( i.e . Paget Disease , Osteogenesis Imperfecta , HIV ) exclude study . History pancreatitis</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>sitagliptin</keyword>
	<keyword>Januvia</keyword>
</DOC>